Wanbangde Pharmaceutical Holding Group Co., Ltd. (SHE:002082)

SHE:002082 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,443	1,531	1,770	1,923	13,678
Other Revenue	-	10.51	16.46	7.86	23.67
Revenue	1,443	1,542	1,786	1,931	13,702
Revenue Growth (YoY)	-6.39%	-13.69%	-7.47%	-85.91%	-17.91%
Cost of Revenue	839.62	918.18	852.57	999.27	12,364
Gross Profit	603.75	623.76	933.85	931.33	1,338
Selling, General & Admin	445.17	458.13	579.71	571.77	672.45
Research & Development	59.87	53.98	59.1	76.2	184.89
Other Operating Expenses	9.59	17.89	23.48	20.43	22.7
Operating Expenses	514.63	553.57	701.27	720.65	899.44
Operating Income	89.12	70.19	232.58	210.69	438.07
Interest Expense	-	-46.48	-33.2	-35.6	-56.68
Interest & Investment Income	17.29	5.19	10.75	235.76	18.47
Currency Exchange Gain (Loss)	-	-4.53	-0.82	-0.93	1.81
Other Non Operating Income (Expenses)	-39	-1.41	-0.74	-1.27	-8.69
EBT Excluding Unusual Items	67.41	22.96	208.58	408.65	392.98
Impairment of Goodwill	-	-	-67.78	-19.27	-74.4
Gain (Loss) on Sale of Investments	2.94	-1.83	-0.56	-2.39	-
Gain (Loss) on Sale of Assets	15.74	0.12	-0.95	-1.21	-0.31
Asset Writedown	-27.14	-2.88	-22.5	-28.09	-1.97
Other Unusual Items	-	11.56	-16.66	3.46	31.45
Pretax Income	58.95	29.93	100.13	361.14	347.76
Income Tax Expense	13.71	3.6	26.43	199.98	55.54
Earnings From Continuing Operations	45.25	26.33	73.71	161.16	292.21
Minority Interest in Earnings	10.19	22.88	19.55	5.35	-7.28
Net Income	55.44	49.21	93.26	166.51	284.94
Net Income to Common	55.44	49.21	93.26	166.51	284.94
Net Income Growth	12.67%	-47.23%	-43.99%	-41.56%	-3.26%
Shares Outstanding (Basic)	616	615	622	617	606
Shares Outstanding (Diluted)	616	615	622	617	606
Shares Change (YoY)	0.15%	-1.06%	0.82%	1.73%	21.45%
EPS (Basic)	0.09	0.08	0.15	0.27	0.47
EPS (Diluted)	0.09	0.08	0.15	0.27	0.47
EPS Growth	12.50%	-46.67%	-44.44%	-42.55%	-20.34%
Free Cash Flow	31.79	-201.59	-406.88	-263.42	-408.24
Free Cash Flow Per Share	0.05	-0.33	-0.65	-0.43	-0.67
Dividend Per Share	-	0.080	0.120	-	0.200
Dividend Growth	-	-33.33%	-	-	33.33%
Gross Margin	41.83%	40.45%	52.28%	48.24%	9.76%
Operating Margin	6.17%	4.55%	13.02%	10.91%	3.20%
Profit Margin	3.84%	3.19%	5.22%	8.63%	2.08%
Free Cash Flow Margin	2.20%	-13.07%	-22.78%	-13.64%	-2.98%
EBITDA	190.18	162.47	337.3	305.12	545.18
EBITDA Margin	13.18%	10.54%	18.88%	15.80%	3.98%
D&A For EBITDA	101.07	92.28	104.72	94.43	107.11
EBIT	89.12	70.19	232.58	210.69	438.07
EBIT Margin	6.17%	4.55%	13.02%	10.91%	3.20%
Effective Tax Rate	23.25%	12.04%	26.39%	55.37%	15.97%
Revenue as Reported	-	1,542	1,786	1,931	13,702
Advertising Expenses	-	3.73	1.32	4.86	3.81

Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.